Three novel radiopharmaceuticals have been evaluated for their potential to be utilized in PET imaging of tau proteins in humans. The results of the study have the potential to improve the way we diagnose and treat Alzheimer’s disease.
Browsing: Cognitive/neurodegenerative disorders
Research demonstrates that female mice display a unique pattern of fluctuation in sex hormones during the ovarian cycle that could be linked to cognitive impairments such as Alzheimer’s disease.
Aoife Kiely, from our partner Alzheimer’s Society (London, UK), provides us with an overview on Brains for Dementia Research.
Researchers have demonstrated that a DNA vaccine tested in mice is effective at reducing accumulation of tau and beta-amyloid proteins associated with Alzheimer’s disease.
Research presented at SfN has provided insight into the neural risks and benefits of marijuana use, including development and Alzheimer’s disease.
Five studies presented at SfN collectively delve into why a healthy heart and lungs may guard against Alzheimer’s disease and vascular dementia.
New studies reveal that exosomes transported between cells produce a wide-range of effects neurologically and throughout the body, from passing the effects of trauma onto the next generation to helping neurons communicate.
Gene therapy for disorders such as amyotrophic lateral sclerosis, Parkinson’s disease and Batten disease has seen success in animal models.
Largest study of its kind reveals that the appendix could act as a reservoir for disease-associated proteins related to Parkinson’s disease.
In a Phase III clinical trial, a novel drug termed GV-971 has shown promise for improving cognition in people with mild-to-moderate Alzheimer’s disease.